COVID-19 Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Anti-viral, Monoclonal Antibodies, Kinase Inhibitors, Others (anti-inflammatory drugs, convalescent plasma, others)), By Region, And By Segment Forecasts, 2025-2034

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global COVID-19 Therapeutics Market Snapshot Chapter 4. Global COVID-19 Therapeutics Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Industry Analysis – Porter's Five Forces Analysis 4.7. Competitive Landscape & Market Share Analysis 4.8. Impact of Covid-19 Analysis 4.9. Clinical Trial Analysis/Pipeline Analysis 2021 Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis 5.1. By Drug Class & Market Share, 2024 & 2034 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Class: 5.2.1. Corticosteroids 5.2.1.1. Dexamethasone 5.2.1.2. Hydrocortisone 5.2.1.3. Methylprednisolone 5.2.1.4. Others (Prednisone, Others) 5.2.2. Anti-viral 5.2.2.1. Remdesivir 5.2.2.2. Nirmatrelvir 5.2.2.3. Others (Ivermectin, Others) 5.2.3. Monoclonal Antibodies 5.2.3.1. Sotrovimab 5.2.3.2. Casirivimab plus imdevimab 5.2.3.3. Others (Bamlanivimab plus etesevimab, Tixagevimab plus, cilgavimab, others) 5.2.4. Kinase Inhibitors 5.2.4.1. Baricitinib 5.2.4.2. Others (Tofacitinib, Others) 5.2.5. Others (anti-inflammatory drugs, convalescent plasma, others) Chapter 6. COVID-19 Therapeutics Market Segmentation 2: Regional Estimates & Trend Analysis 6.1. North America 6.1.1. North America COVID-19 Therapeutics Market revenue (US$ Million) estimates and forecasts By Drug Class, 2021-2034 6.1.2. North America COVID-19 Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034 6.2. Europe 6.2.1. Europe COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2021-2034 6.2.2. Europe COVID-19 Therapeutics Market revenue (US$ Million) by country, 2021-2034 6.3. Asia Pacific 6.3.1. Asia Pacific COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2021-2034 6.3.2. Asia Pacific COVID-19 Therapeutics Market revenue (US$ Million) by country, 2021-2034 6.4. Latin America 6.4.1. Latin America COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2021-2034 6.4.2. Latin America COVID-19 Therapeutics Market revenue (US$ Million) by country, 2021-2034 6.5. Middle East & Africa 6.5.1. Middle East & Africa COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2021-2034 6.5.2. Middle East & Africa COVID-19 Therapeutics Market revenue (US$ Million) by country, 2021-2034 Chapter 7. Competitive Landscape 7.1. Major Mergers and Acquisitions/Strategic Alliances 7.2. Company Profiles 7.2.1. AstraZeneca plc 7.2.2. Celltrion Healthcare Co.,Ltd 7.2.3. Pfizer Inc. 7.2.4. Ridgeback Biotherapeutics 7.2.5. Merck & Co. 7.2.6. Veru Inc. 7.2.7. Gilead Sciences, Inc. 7.2.8. GSK plc 7.2.9. Shionogi & Company, Limited 7.2.10. NRx Pharmaceuticals, Inc. 7.2.11. Kintor Pharma-B 7.2.12. Regeneron Pharmaceuticals 7.2.13. CytoDyn 7.2.14. Atea Pharmaceuticals, Inc. 7.2.15. Amarin Corporation 7.2.16. APEIRON Biologics AG 7.2.17. Abivax SA 7.2.18. Alexion Pharmaceuticals 7.2.19. Bellerophon Therapeutics 7.2.20. Blade Therapeutics, Inc 7.2.21. Roivant Sciences 7.2.22. Synairgen 7.2.23. Sorrento Therapeutics 7.2.24. Fulcrum Therapeutics 7.2.25. Ono Pharmaceutical Co., Ltd. 7.2.26. Revive Therapeutics Ltd. 7.2.27. Eli Lilly and Company 7.2.28. Other Prominent Players